- Home
- PRPO vs NXL Comparison
PRPO vs NXL Comparison
Compare PRPO & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- NXL
- Stock Information
- Founded
- PRPO N/A
- NXL 2010
- Country
- PRPO United States
- NXL United States
- Employees
- PRPO N/A
- NXL N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- NXL Medical Specialities
- Sector
- PRPO Industrials
- NXL Health Care
- Exchange
- PRPO Nasdaq
- NXL Nasdaq
- Market Cap
- PRPO 12.3M
- NXL 10.0M
- IPO Year
- PRPO N/A
- NXL 2022
- Fundamental
- Price
- PRPO $10.14
- NXL $2.87
- Analyst Decision
- PRPO
- NXL Hold
- Analyst Count
- PRPO 0
- NXL 1
- Target Price
- PRPO N/A
- NXL N/A
- AVG Volume (30 Days)
- PRPO 13.1K
- NXL 377.2K
- Earning Date
- PRPO 03-28-2025
- NXL 03-26-2025
- Dividend Yield
- PRPO N/A
- NXL N/A
- EPS Growth
- PRPO N/A
- NXL N/A
- EPS
- PRPO N/A
- NXL N/A
- Revenue
- PRPO $17,411,000.00
- NXL $162,078.00
- Revenue This Year
- PRPO $75.18
- NXL $56.86
- Revenue Next Year
- PRPO N/A
- NXL $167.44
- P/E Ratio
- PRPO N/A
- NXL N/A
- Revenue Growth
- PRPO 31.31
- NXL 26.00
- 52 Week Low
- PRPO $4.31
- NXL $0.30
- 52 Week High
- PRPO $10.74
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- PRPO 85.00
- NXL 42.81
- Support Level
- PRPO $7.02
- NXL $2.80
- Resistance Level
- PRPO $7.54
- NXL $3.54
- Average True Range (ATR)
- PRPO 0.50
- NXL 0.38
- MACD
- PRPO 0.29
- NXL -0.02
- Stochastic Oscillator
- PRPO 85.72
- NXL 14.53
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.